We have shown that a combination of SRC and MEK inhibition synergistically inhibits the growth of ovarian cancer cell lines, and that MEK inhibition is sufficient to resenesitize ovarian cancer cell lines with acquired resistance to saracatinib (AZD0530). This evidence concerns the gene MAP2K7 and ovarian cancer.